Recruitment unclearEUCTR 2022-000618-32

Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy...

This historical record does not confirm current site availability.

Historical research recordItaly + SpainMental health

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Italy · Spain
Study phase: Phase 2

Get this study by email

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Recruitment unclear
Enrollment listed in the registry: 182
Sponsor: GENEURO SA
Sponsor type: Other organization
Study type: Biological
Intervention type: BIOLOGICAL
Study phase: Phase 2
Locations: Italy, Spain
Age range: Not clearly listed
Official registry ID: EUCTR 2022-000618-32
Official title: Show the full official title
Temelimab as a Disease Modifying Therapy in Patients with Neurological, Neuropsychological, and Psychiatric (=Neuropsychiatric) Symptoms in Post-COVID-19 or Postacute Sequelae of COVID-19 (PASC) Sy...

Recruitment & locations

Status unknown

Italy · Spain

Registry details

Historical country statuses

Spain — Ongoing
Italy — Completed

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is GENEURO SA.

Want to explore more studies?

Explore studies